Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | TACR1 | P25103 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL321594 | 0.88 | USP2 (0.49) | USP2SMN1; SMN2NR1H2HPGDEPHX2 | |
| SCHEMBL20870087 | 0.84 | USP2 (0.49) | USP2SMN1; SMN2GPR119HPGDCYP2D6 | |
| SCHEMBL27302816 | 0.84 | USP2 (0.45) | USP2SMN1; SMN2GPR119NR1H2HPGD | |
| SCHEMBL15715964 | 0.82 | USP2 (0.42) | USP2SMN1; SMN2NR1H2HPGDHDAC2 | |
| SCHEMBL21216177 | 0.82 | USP2 (0.42) | USP2SMN1; SMN2NR1H2HPGDHDAC2 | |
| SCHEMBL19459465 | 0.82 | USP2 (0.42) | USP2SMN1; SMN2NR1H2HPGDHDAC2 | |
| SCHEMBL10172533 | 0.80 | USP2 (0.50) | USP2SMN1; SMN2GPR119NR1H2HPGD | |
| SCHEMBL27301647 | 0.79 | USP2 (0.44) | USP2SMN1; SMN2GPR119HPGDHDAC1 | |
| SCHEMBL346995 | 0.79 | USP2 (0.56) | USP2SMN1; SMN2GPR119HPGDCYP2D6 | |
| SCHEMBL22814433 | 0.79 | USP2 (0.46) | USP2SMN1; SMN2GPR119HPGDHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4626554-A1 | GLUTARIMIDE-CONTAINING KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF | Tiger Biotherapeutics Inc. (US) | 2025-10-08 | — | — | EP | disclosed |
| EP-4626555-A1 | GLUTARIMIDE-CONTAINING PAN-KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF | Tiger Biotherapeutics Inc. (US) | 2025-10-08 | — | — | EP | disclosed |
| US-20250092039-A1 | GLUTARIMIDE-CONTAINING PAN-KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF | TIGER BIOTHERAPEUTICS INC. | 2025-03-20 | — | — | US | disclosed |
| US-12195459-B2 | Glutarimide-containing pan-KRAS-mutant degrader compounds and uses thereof | TIGER BIOTHERAPEUTICS INC. (US) | 2025-01-14 | — | — | US | disclosed |
| US-12168058-B2 | Glutarimide-containing KRAS-mutant degrader compounds and uses thereof | Tiger Biotherapeutics, Inc. (US) | 2024-12-17 | — | — | US | disclosed |
| US-12110291-B2 | Glutarimide-containing pan-KRAS-mutant degrader compounds and uses thereof | TIGER BIOTHERAPEUTICS INC. (US) | 2024-10-08 | — | — | US | disclosed |
| US-20240294527-A1 | GLUTARIMIDE-CONTAINING PAN-KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF | TIGER BIOTHERAPEUTICS INC. | 2024-09-05 | — | — | US | disclosed |
| US-20240216516-A1 | GLUTARIMIDE-CONTAINING KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF | TIGER BIOTHERAPEUTICS INC. | 2024-07-04 | — | — | US | disclosed |
| US-20240217972-A1 | GLUTARIMIDE-CONTAINING PAN-KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF | TIGER BIOTHERAPEUTICS INC. | 2024-07-04 | — | — | US | disclosed |
| US-20240216516-A1 | GLUTARIMIDE-CONTAINING KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF | TIGER BIOTHERAPEUTICS INC. | 2024-07-04 | — | — | US | disclosed |
| US-20240217972-A1 | GLUTARIMIDE-CONTAINING PAN-KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF | TIGER BIOTHERAPEUTICS INC. | 2024-07-04 | — | — | US | disclosed |
| US-20240216516-A1 | GLUTARIMIDE-CONTAINING KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF | TIGER BIOTHERAPEUTICS INC. | 2024-07-04 | — | — | US | disclosed |
| WO-2024118960-A1 | GLUTARIMIDE-CONTAINING KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF | TIGER BIOTHERAPEUTICS INC. (US) | 2024-06-06 | — | — | WO | disclosed |
| WO-2024118966-A1 | GLUTARIMIDE-CONTAINING PAN-KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF | TIGER BIOTHERAPEUTICS INC. (US) | 2024-06-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240216516-A1 | GLUTARIMIDE-CONTAINING KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF | KRAS, VHL, HRAS | USP2 144/4885SMN1; SMN2 1213/4885GPR119 1917/4885 |
| US-20250092039-A1 | GLUTARIMIDE-CONTAINING PAN-KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF | KRAS, VHL, HRAS | USP2 100/4885SMN1; SMN2 2182/4885GPR119 1296/4885 |
| US-12110291-B2 | Glutarimide-containing pan-KRAS-mutant degrader compounds and uses thereof | KRAS, VHL, HRAS | USP2 100/4885SMN1; SMN2 2182/4885GPR119 1296/4885 |
| US-12168058-B2 | Glutarimide-containing KRAS-mutant degrader compounds and uses thereof | KRAS, VHL, HRAS | USP2 144/4885SMN1; SMN2 1213/4885GPR119 1917/4885 |
| US-20240217972-A1 | GLUTARIMIDE-CONTAINING PAN-KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF | KRAS, VHL, HRAS | USP2 100/4885SMN1; SMN2 2182/4885GPR119 1296/4885 |
| US-20240294527-A1 | GLUTARIMIDE-CONTAINING PAN-KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF | KRAS, VHL, HRAS | USP2 100/4885SMN1; SMN2 2182/4885GPR119 1296/4885 |
| US-12195459-B2 | Glutarimide-containing pan-KRAS-mutant degrader compounds and uses thereof | KRAS, VHL, HRAS | USP2 100/4885SMN1; SMN2 2182/4885GPR119 1296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.